Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2005;331:263 (30 July), doi:10.1136/bmj.38476.471088.3A (published 19 May 2005)
Liat Vidal, physician, research unit1, Maya Shavit, pharmacist, research unit1, Abigail Fraser, head of research unit1, Mical Paul, attending physician1, Leonard Leibovici, head of department1
1 Department of Medicine E, Beilinson Campus, Rabin Medical Center, Petah-Tiqva, Israel
Correspondence to: L Leibovici leibovic{at}post.tau.ac.il
Design Systematic comparison of the definitions of renal impairment, recommendations for dosage adjustment, and the evidence in support of these recommendations in four information sources.
Data sources British National Formulary, Martindale: the Complete Drug Reference, American Hospital Formulary System Drug Information, and Drug Prescribing in Renal Failure.
Review methods Two reviewers independently extracted data on recommendations for dosage adjustment for impaired renal function of 100 drugs often used in our hospital.
Results The four sources differed in their recommendations for adjustments of dosage and dosing interval. They vary in their definitions of renal impairment; some are qualitative and remain unclear. All sources provide only a general description; the methods on which the advice is based and references for original data are rarely presented.
Conclusions The remarkable variation in definitions and recommendations, along with scarce details of the methods used to reach this advice, makes the available sources of drug information ill suited for clinical use. The methods used to retrieve information and use data should be described and made available to the reader. Advice on drug prescription, dose and dosing interval, contraindications, and adverse effects should be evidence based.
We originally intended to use the British National Formulary as the primary source,1 but for many drugs the BNF gave only a general warning, without explicit advice on how to adjust the dose or dosing interval. We consulted three other secondary sources of pharmacotherapy that are used in our hospital: Martindale: the Complete Drug Reference,2 American Hospital Formulary System (AHFS) Drug Information,3 and Drug Prescribing in Renal Failure.4 The extent of information in the four sources varied, and discrepancies between their recommendations were soon evident. In order to decide on a source (or sources) to use, we compared the four sources.
We extracted data for 100 drugs that were most often prescribed in our hospital during 2003, judging by the defined daily dose (DDD) consumption (DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults; see bmj.com).
All sources provide only general information on their decision making process regarding adjustments for renal function. This information is not detailed enough to help users reach primary sources or reconstruct the process (see bmj.com).
The different sources expressed recommendations in quantitative and qualitative terms. None of the qualitative terms is defined. We grouped the terms into several categories (table 1) to compare them.
|
We also looked at the references quoted to support recommendations. The BNF cited no references, and the practice of the other three sources varied (table 2).
|
Recommendations and comparisons
The BNF recommends some form of adjustment for impaired renal function for 51 drugs (54%), Martindale for 62 drugs (62%), AHFS Drug Information for 50 drugs (56%), and Drug Prescribing in Renal Failure for 36 drugs (53%). Precise recommendations (numerical adjustment or avoid) were advised for 25 drugs in the BNF, 34 in Martindale, 23 in AHFS Drug Information, and 35 in Drug Prescribing in Renal Failure (table 3).
|
|
We further examined how drugs that required no adjustment according to one source were categorised by a second source (table 4). The differences were remarkablefor example, 11 drugs (26%) out of 43 for which the BNF recommended no adjustment were categorised by Martindale as requiring it (dexamethasone, prednisone, methylprednisolone, hydrocortisone, paracetamol, amiodarone, promethazine, isosorbide mononitrate, isosorbide dinitrate, progesterone, loratadine). We also looked for information on the need to adjust dosage according to renal function by searching Medline, combining the names of the 11 drugs with the MESH terms for kidney failure, glomerular filtration rate, pharmacokinetics, and adverse events. We attained helpful articles for only five drugs (paracetamol, amiodarone, isosorbide dinitrate, loratadine, and promethazine).
|
In seven instances (six drugs) a drug that required no adjustment according to one source was categorised as contraindicated in patients with impaired renal function by a second source (table 4).
Limitations of the study
Our analysis is limited by several factors. We looked at only four secondary sources of information in common use in our hospital and health maintaining organisation (Clalit Health Services), but the chance that more sources will reduce the variability between sources is small. We based our comparison on 100 drugs that are consumed most often in our hospital. We have little reason to assume that the choice was biased and included problematic drugs. We tackled only adjustments for renal impairment, but we can guess that the adjustment for liver failure, for example, is no better described or referenced.
Conclusions
Looking for evidence on the efficiency of interventions, clinicians are taught to expect secondary sources (for example, systematic reviews in the Cochrane Library) to use their primary sources in a methodical manner: transparent and reproducible workflow, a thorough and explicit search for references, elimination of bias, and a short description of the primary sources. What should clinicians (and their patients) expect from a reliable secondary source of drug information? The methods used to retrieve information and data on use should be described and made available to the readerfor example, which kind of data are solicited from the manufacturer, how their reliability is judged, and how the data are translated into quantitative recommendations. Readers should be told if other sources of primary information are searched, which methods are used to search them, and again how the information is translated into recommendations. Primary data should be summarised, and the reader should have easy access to it. If possible, quantitative recommendations on dosages and dosing intervals should be made. If not, the reason for the qualitative recommendation should be made clear. The basics of drug prescriptiondosage and dosing interval, contraindications, and expected adverse effectsshould be no less evidence based than the efficacy and effectiveness of a drug or intervention.
|
Contributors: LV, MS, and LL had the idea for the article. LV, MS, AF, and MP performed searches and data collection. LV and LL wrote the article and are guarantors.
Funding: EC 6th Framework IST grant, AMICA, contract number 507048.
Competing interests: None declared.
Ethical approval: Not required.
Read all Rapid Responses
What can you learn from this BMJ paper? Read Leanne Tite's Paper+